Pacific Edge reviews US pricing for new Cxbladder test, trading halted

Pacific Edge reviews US pricing for new Cxbladder test, trading halted
Pacific Edge says Cxbladder Triage Plus delivers “significant performance improvements” compared to its existing tests. (Image: Pacific Edge)
Rebecca Howard
Pacific Edge has been placed on a trade halt while it reviews draft gapfill or reimbursement rates for its new Cxbladder Triage Plus test from the US Centres for Medicare and Medicaid Services.“[It said it's] reviewing the prices and the associated documentation and needs time to assess the implications of them, consult with its advisers and industry partners, and prepare an announcement that provides context to investors.”Gapfill prices are proposed reimbursement rates for new or unpriced clinical diagnostic laboratory tests.Th...

More Markets

Property companies help boost NZ sharemarket
Markets Market Close

Property companies help boost NZ sharemarket

Ryman Healthcare, Argosy Property and Goodman all saw share-price rises.

Tom Raynel 05 Jun 2025
Genesis takes another step in increasing NZ's battery capacity
Markets

Genesis takes another step in increasing NZ's battery capacity

Grid-scale batteries add to the mix, but questions remain over economic viability.

Ian Llewellyn 05 Jun 2025
NZ sharemarket rises strongly on power company gains
Markets Market Close

NZ sharemarket rises strongly on power company gains

Positive day for Mercury and Meridian as well as a2 Milk despite gloom on global front. 

Tom Raynel 04 Jun 2025